Rehabilitation program for core muscle control in patients with multiple sclerosis

Evaluation of the Influence of a Core Muscle Control-Based Rehabilitation Program on Pelvic Floor Function in Patients With Multiple Sclerosis

Not applicable Interventional Universidad Europea de Madrid · NCT06384716

This study is testing a rehabilitation program that helps people with multiple sclerosis improve their core muscle control to see if it can make them feel better and improve their daily life.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment32 (estimated)
Ages18 Years to 70 Years
SexAll
SponsorUniversidad Europea de Madrid Academic / other
Locations1 site (Madrid)
Trial IDNCT06384716 on ClinicalTrials.gov

What this trial studies

This study evaluates the effectiveness of a rehabilitation program focused on core muscle control for patients with multiple sclerosis. The intervention aims to improve pelvic floor functionality, urinary incontinence, sexual dysfunction, balance, and respiratory function. Participants will undergo a structured training regimen designed to enhance their overall motor control and assess its impact on their quality of life. The study will include patients aged 18 to 70 with a confirmed diagnosis of multiple sclerosis and specific disability criteria.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 to 70 with a confirmed diagnosis of multiple sclerosis and experiencing urinary incontinence.

Not a fit: Patients with other neurological diseases or significant cognitive impairments may not benefit from this study.

Why it matters

Potential benefit: If successful, this program could significantly improve the quality of life and functional abilities of patients with multiple sclerosis.

How similar studies have performed: While similar approaches have been explored, this specific intervention focusing on core muscle control in multiple sclerosis is relatively novel.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

* - Age between 18 and 70 years.
* Confirmed diagnosis of Multiple Sclerosis based on McDonald criteria, with an evolution time of more than two years (remitting or progressive) (24).
* Multiple Sclerosis Disability Status Scale (EDSS) score between 2 (minimal disability in one of the functional systems), and 7.5 (inability to take more than a few steps. Limited to wheelchair and transfer support. Ability to move the chair, but not all day if the chair is conventional and lacks a motor) (25, 26).
* Stable medical treatment for at least six months prior to surgery (26).
* Absence of cognitive impairment, with ability to understand instructions and score 24 or higher on the Minimental Test (27).
* Urinary incontinence as a consequence of neurological involvement.

Exclusion Criteria:

* - Diagnosis of another neurological disease or musculoskeletal disorder other than MS.
* Diagnosis of any cardiovascular, respiratory, genitourinary, metabolic or other conditions that may interfere with this study.
* Having presented urinary incontinence prior to the diagnosis of MS.
* Have suffered an exacerbation or hospitalisation in the last 3 months before starting the assessment protocol, or during the therapeutic intervention process.
* Have received a course of intravenous or oral steroids 6 months prior to the start of the assessment protocol and within the intervention period of the study duration.

Where this trial is running

Madrid

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions Multiple SclerosisPelvic Floor DisordersIncontinence, Urinary
Last reviewed 2026-06-09 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.